دورية أكاديمية
Knowledge about and attitude toward cosmeceuticals among pharmacists in Saudi Arabia.
العنوان: | Knowledge about and attitude toward cosmeceuticals among pharmacists in Saudi Arabia. |
---|---|
المؤلفون: | Almeman AA; Pharmacology and Therapeutic Department, College of Medicine, Qassim, Qassim University, Buraidah, Saudi Arabia. |
المصدر: | Journal of cosmetic dermatology [J Cosmet Dermatol] 2020 Nov; Vol. 19 (11), pp. 2946-2952. Date of Electronic Publication: 2020 Mar 11. |
نوع المنشور: | Journal Article; Observational Study |
اللغة: | English |
بيانات الدورية: | Publisher: Blackwell Science Country of Publication: England NLM ID: 101130964 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1473-2165 (Electronic) Linking ISSN: 14732130 NLM ISO Abbreviation: J Cosmet Dermatol Subsets: MEDLINE |
أسماء مطبوعة: | Original Publication: Oxford, UK : Blackwell Science, c2002- |
مواضيع طبية MeSH: | Cosmeceuticals*, Cross-Sectional Studies ; Female ; Health Knowledge, Attitudes, Practice ; Humans ; Male ; Pharmacists ; Saudi Arabia |
مستخلص: | Background: Whitening cosmeceuticals are commonly used for beauty purposes and managing pigmentation disorders. There is significant variability across the world with regard to knowledge as well as legislation of cosmeceuticals. Aim: To evaluate the knowledge of and attitude toward whitening cosmeceuticals among pharmacists in Saudi Arabia. Methods: This was a descriptive cross-sectional observational study based on an online survey conducted between February and August 2019. The participants were registered pharmacists in different sectors in Saudi Arabia. The study was approved by the Ethics Committee of Qassim, Ministry of Health. The pharmacists' response to questions on demographic characteristics, occupation, knowledge, and attitude toward whitening cosmeceuticals were collected in an online sheet. Results: In all, 584 pharmacists completed the survey; of these, 5.49%, 24.82%, and 70% were consultants, pharmacists I, and pharmacists, respectively. The male-to-female ratio was 1.6:1. The most common response in the survey is "I don't know." Interestingly, 324 (59.12%) of the participants could define whitening cosmeceuticals, but 520 (90%) did not identify the term's source. Regarding practice, 196 (35.77%) participants had never used a whitening cosmetic, whereas 72 (13.14%) had but could not identify the agent. Forty percent of the participants were unaware of the possibility of combining two or more whitening cosmeceuticals and 13.14% thought that such combinations are contraindicated. Conclusion: There is significant variability among pharmacists in Saudi Arabia regarding the understanding and practice of whitening cosmeceuticals. Our results indicate that further measures are essential for increasing the awareness of pharmacists in Saudi Arabia. (© 2020 Wiley Periodicals, Inc.) |
References: | Kligman A. The future of cosmeceuticals: an interview with Albert Kligman, MD, PhD. Interview by Zoe Diana Draelos. Dermatol Surg. 2005;31:890-891. Amer M, Maged M. Cosmeceuticals versus pharmaceuticals. Clin Dermatol. 2009;27:428-430. Wu C, Wu H-T, Wang Q, et al. Anticandidal potential of stem bark extract from Schima superba and the identification of its major anticandidal compound. Molecules. 2019;24:pii:E1587. Baumann L. Cosmeceuticals in skin of color. Semin Cutan Med Surg. 2016;35:233-237. Nomakhosi M, Heidi A. Natural options for management of melasma, a review. J Cosmet Laser Ther. 2018;20:470-481. Pandey A, Jatana GK,Sonthalia S. Cosmeceuticals. In: StatPearls. Treasure Island, FL: StatPearls Publishing. 2019. https://www.ncbi.nlm.nih.gov/books/NBK544223/. Draelos ZD. Cosmeceuticals: undefined, unclassified, and unregulated. Clin Dermatol. 2009;27:431-434. De Salva SJ. Safety evaluation of over-the-counter products. Regul Toxicol Pharmacol. 1985;5:101-108. FDA. Cosmeceuticals. 2018. https://www.fda.gov/cosmetics/cosmetics-labeling-claims/cosmeceutical. Published July 6, 2017. Accessed January 17, 2020. Manual on the scope of application of the Cosmetics Regulation (EC) No 1223/2009 (Art. 2(1)(a)) (April 2018) Document date: 03/12/2018 - Created by GROW.DDG1.D.4. https://ec.europa.eu/docsroom/documents/29002.0. Published December 03, 2018. Accessed January 17, 2020. Rossi E, Prlic A, Hoffman R. A Study of the European Cosmetics Industry Final Report Prepared for: European Commission, Directorate General for Enterprise and Industry Prepared by: Global Insight, Inc. October 2007 Ref. Ares(2015)4280187 - 14/10/2015. http://ec.europa.eu/DocsRoom/documents/13125/attachments/1/translations/en/renditions/pdf. Published October 01, 2007. Accessed January 17, 2020. SFDA Products Classification Guidance 3.1. 2019. https://www.sfda.gov.sa/ar/oper/Documents/SFDAProductsClassificationGuidance.pdf. Accessed January 17, 2020. Hexsel CL, Bangert SD, Hebert AA, Lim HW. Current sunscreen issues: 2007 Food and Drug Administration sunscreen labelling recommendations and combination sunscreen/insect repellent products. J Am Acad Dermatol. 2008;59:316-323. Brandt FS, Cazzaniga A, Hann M. Cosmeceuticals: current trends and market analysis. Semin Cutan Med Surg. 2011;30:141-143. Draelos ZD. Cosmeceuticals: efficacy and influence on skin tone. Dermatol Clin. 2014;32:137-143. Lintner K, Mas-Chamberlin C, Mondon P, Peschard O, Lamy L. Cosmeceuticals and active ingredients. Clin Dermatol. 2009;27:461-468. Ebada MA, Alkanj S, Ebada M, et al. Safety and efficacy of levetiracetam for the management of levodopa-induced dyskinesia in patients with Parkinson’s disease: a systematic review. CNS Neurol Disord Drug Targets. 2019;18:317-325. Epstein H. Cosmeceutical vehicles. Clin Dermatol. 2009;27:453-460. Regulation (EC) No 1223/2009 of the European Parliament and of the Council of 30 November 2009 on cosmetic products. EUR- Lex Access to European Union Law. http://data.europa.eu/eli/reg/2009/1223/2019-08-13. Published November 30, 2009. Accessed January 17, 2020. Akbarsha MA, Mascarenhas B. Cosmetic Regulation and Alternatives to Animal Experimentation in India. Springer Link. https://link.springer.com/chapter/10.1007/978-981-13-2447-5_7. Published December 28, 2018. Accessed January 17, 2020. Knight J, Rovida C. Safety evaluations under the proposed US safe cosmetics and personal care products act of 2013: animal use and cost estimates. ALTEX. 2014;31(2):177-208. Elhussein BA, Babikr WG, Helali R. Knowledge, attitude and practice concerning using cosmetic among females at Najran University, Saudi Arabia. IOSR J Pharm Biol Sci. 2016;11:46-50. Alanzi ME, Alghamdi RA, Alsharif OM, Alghamdi KS, El Sayed SM. Health knowledge, cosmetic interests, attitude, and the need for health education regarding the use of topical bleaching agents among women in West Saudi Arabia: a Cross-Sectional Study. J Cosmet Sci. 2018;69:101-120. Serrano-Dedicatoria M. Knowledge, attitudes, practices (KAP) and sources of information on safe cosmetics and personal-care products among journalists in a major Philippine newspaper. 2015:32. Philppine Open University. https://www.researchgate.net/publication/281852029_Knowledge_Attitudes_Practices_KAP_and_Sources_of_Information_on_Safe_Cosmetics_and_Personalcare_Products_among_Journalists_in_a_Major_Philippine_Newspaper. Accessed January 20, 2020. Peltzer K, Pengpid S, James C. The globalization of whitening: prevalence of skin lighteners (or bleachers) use and its social correlates among university students in 26 countries. Int J Dermatol. 2016;55:165-172. Peltzer K, Pengpid S. Knowledge about, attitude toward, and practice of skin lightening products use and its social correlates among university students in five Association of Southeast Asian Nations (ASEAN) countries. Int J Dermatol. 2017;56:277-283. Nordlund JJ, Grimes PE, Ortonne JP. The safety of hydroquinone. J Eur Acad Dermatol Venereol. 2006;20:781-787. Garcia A, Fulton JE Jr. The combination of glycolic acid and hydroquinone or kojic acid for the treatment of melasma and related conditions. Dermatol Surg. 1996;22:443-447. Boissy RE, Visscher M, DeLong MA. DeoxyArbutin: a novel reversible tyrosinase inhibitor with effective in vivo skin lightening potency. Exp Dermatol. 2005;14:601-608. Findlay GH. Ochronosis following skin bleaching with hydroquinone. J Am Acad Dermatol. 1982;6:1092-1093. Burnett CL, Bergfeld WF, Belsito DV, et al. Final report of the safety assessment of Kojic acid as used in cosmetics. Int J Toxicol. 2010;29:244-273. Sarkar R, Arora P, Garg KV. Cosmeceuticals for hyperpigmentation: what is available? J Cutan Aesthet Surg. 2013;6:4-11. Degen GH. Opinion of the Scientific Committee on Consumer safety (SCCS)-Opinion on the safety of the use of α-arbutin in cosmetic products. Regul Toxicol Pharmacol. 2016;74:75-76. Choi YK, Rho YK, Yoo KH, et al. Effects of vitamin C vs. multivitamin on melanogenesis: comparative study in vitro and in vivo. Int J Dermatol. 2010;49:218-226. |
فهرسة مساهمة: | Keywords: Saudi Arabia; knowledge; pharmacists; skin bleaching; whitening cosmeceuticals |
المشرفين على المادة: | 0 (Cosmeceuticals) |
تواريخ الأحداث: | Date Created: 20200313 Date Completed: 20210514 Latest Revision: 20210514 |
رمز التحديث: | 20221213 |
DOI: | 10.1111/jocd.13358 |
PMID: | 32162468 |
قاعدة البيانات: | MEDLINE |
تدمد: | 1473-2165 |
---|---|
DOI: | 10.1111/jocd.13358 |